8-K current report · filed Nov 4, 2026

Revolution Medicines Inc (RVMD) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1RVMD overview

Short answer

Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

Revolution Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1
  • Investor focus: cash runway, RAS oncology pipeline progress and development spending in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • RASONQUE U.S. launch generated $197.6 million revenue in roughly five weeks, establishing Revolution Medicines as a commercial-stage oncology company
  • More than 5,000 patients received RASONQUE, while payer claims covered over 90% of U.S. PDAC lives, supporting early access momentum
  • Cash and marketable securities reached $3.7 billion, excluding $250 million received in October from Royalty Pharma debt financing
  • R&D rose to $417.1 million and SG&A to $153.3 million, reflecting intensified pipeline investment and commercialization costs
  • Net loss widened to $407.5 million, while full-year 2026 operating expense guidance remained $2.1 billion to $2.2 billion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revolution Medicines Inc 8-K filings

Get the next RVMD 8-K as it lands

Follow RVMD for push alerts, or ask the research agent what this filing means.